Ipsen SA

IPSEN - Buy-back programme - Art 5 of MAR - Week 33 - 2023

22 Aug 2023 11:00:00 By Nasdaq GlobeNewswire

Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer

21 Aug 2023 00:00:00 By Nasdaq GlobeNewswire

US FDA approves Ipsen’s SohonosTM (palovarotene) capsules, the first and only treatment for people with fibrodysplasia ossificans progressiva

16 Aug 2023 14:32:04 By Nasdaq GlobeNewswire

IPSEN - Buy-back programme - Art 5 of MAR - Week 32 - 2023

16 Aug 2023 04:50:28 By Nasdaq GlobeNewswire

IPSEN - Buy-back programme - Art 5 of MAR - Week 31 - 2023

08 Aug 2023 11:00:00 By Nasdaq GlobeNewswire

Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital

04 Aug 2023 11:00:00 By Nasdaq GlobeNewswire

IPSEN - Buy-back programme - Art 5 of MAR - Week 30 - 2023

01 Aug 2023 11:00:00 By Nasdaq GlobeNewswire

Ipsen S.A. publishes its 2023 Half-Year Financial Report

27 Jul 2023 11:06:16 By Nasdaq GlobeNewswire

Ipsen delivers solid H1 2023 results and upgrades its full-year guidance

27 Jul 2023 00:00:00 By Nasdaq GlobeNewswire

IPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2023

25 Jul 2023 11:00:00 By Nasdaq GlobeNewswire

Correction: Ipsen provides update on E.U. Marketing Authorization Application for Bylvay® for cholestatic pruritus in patients with Alagille syndrome  

21 Jul 2023 06:52:31 By Nasdaq GlobeNewswire

Ipsen announces European Commission decision on palovarotene for the treatment of FOP

19 Jul 2023 11:42:05 By Nasdaq GlobeNewswire

IPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2023

18 Jul 2023 11:00:00 By Nasdaq GlobeNewswire

IPSEN - Buy-back programme - Art 5 of MAR - Week 27 - 2023

11 Jul 2023 11:00:00 By Nasdaq GlobeNewswire

Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital

10 Jul 2023 11:00:00 By Nasdaq GlobeNewswire

Ipsen – Half year statement – 2023 06 30

10 Jul 2023 11:00:00 By Nasdaq GlobeNewswire

IPSEN - Buy-back programme - Art 5 of MAR - Week 26 - 2023

04 Jul 2023 11:00:00 By Nasdaq GlobeNewswire

Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease

30 Jun 2023 00:00:00 By Nasdaq GlobeNewswire

Ipsen announces positive outcome of FDA Advisory Committee on investigational palovarotene for fibrodysplasia ossificans progressiva

28 Jun 2023 19:00:54 By Nasdaq GlobeNewswire

IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2023

27 Jun 2023 11:00:00 By Nasdaq GlobeNewswire